General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
Somewhere in Barnala, Punjab, a 180-acre complex spent three months turning acetic acid into headache tablets and shipping the results to 80 countries, and the June quarter numbers arrived with unusual volume. Revenue from operations was ₹756.26 crore against ₹551.69 crore a year earlier, up 37.1%. Profit after tax was ₹64.48 crore against ₹33.96 crore, up 89.9%. Operating profit came in at ₹103.55 crore versus ₹62.15 crore.
For a company whose quarterly revenue had spent nine consecutive quarters wandering politely between ₹502 crore and ₹619 crore — the corporate equivalent of a treadmill on a gentle incline — a jump of ₹137 crore over the immediately preceding quarter is a change of pace.
Management attributed the profitability to “higher operating leverage, better capacity utilization, improved product mix, and continued focus on operational efficiencies,” which is four phrases doing the work of one, and then pre-emptively dismantled the obvious alternative explanation: asked about inventory gains, management said “this quarter we are not having inventory gain,” and on one-offs, “Nothing… no extraordinary thing.”
Non-ibuprofen products reached 43% of pharma revenue in Q1 FY27 against 36% a year earlier. Exports were 28.5% of revenue against 24.4%. And a molecule almost nobody outside the plasticiser trade has heard of started production in May.
2. Introduction
IOL was incorporated on 29 September 1986 by Varinder Gupta and Rajinder Gupta to set up an acetic acid manufacturing facility, and listed on the BSE in 1991. What followed is one of the more literal build-outs in Indian chemicals: acetic acid first, then ethyl acetate in 1996, acetic anhydride in 1999, and only in 2000 did the company start producing ibuprofen — the product it would eventually dominate globally with a 35% world market share.
The pattern repeats with the persistence of a company that has read exactly one strategy book and liked it. Make the input, then make the thing that needs the input. By 2009 it was producing IBB, MCA and acetyl chloride — the three raw materials ibuprofen requires. A 13 MW co-generation plant followed in 2010, because if you are making everything else you may as well make the electricity. Units 01 through 11 arrived over two decades, each with a dedicated molecule: Unit-04 for metformin, Unit-06 for pantoprazole, Unit-11 for paracetamol at 10,800 MTPA.
Recent moves have kept the rhythm. FY26 saw ethyl acetate capacity raised to 120,000 MTPA, acetic anhydride to 32,000 MTPA, pantoprazole to 276 MTPA, and triacetin installed at 6,000 MTPA. IOL Pharmaxis UK Limited was incorporated in October 2025 as a wholly owned subsidiary; per the auditor’s report, its operations commenced on 2 April 2026 and it entered consolidation for the first time this quarter carrying total assets of ₹0.12 crore and revenue of nil — a subsidiary currently the size of a rounding error, which is where all subsidiaries begin.
On the regulatory side, NMPA China approved Clopidogrel Bisulfate API on 14 July 2026, following ibuprofen’s China approval in April 2025. EDQM issued CEPs for Minoxidil (December 2025), Sitagliptin Phosphate Monohydrate (October 2025), Pantoprazole Sodium Sesquihydrate Process-III (October 2025) and Clopidogrel Besilate (February 2026). The company holds 14 DMFs with USFDA and 21 CEPs with EDQM. The 39th AGM is scheduled for 2 September 2026.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
Two segments, one campus, and a supply chain that mostly talks to itself.
Pharmaceuticals (₹469.49 crore of segment revenue this quarter) makes active pharmaceutical ingredients — the actual drug molecule, before somebody else presses it into a tablet with a brand name and a jingle. The portfolio reads like the contents of a well-stocked medicine cabinet, sorted alphabetically by suffering: ibuprofen and its lysinate, sodium and dex- variants for inflammation, metformin for diabetes, paracetamol for fever, clopidogrel for platelets, pantoprazole for acid, fenofibrate for cholesterol, levetiracetam and lamotrigine for epilepsy, losartan potassium and minoxidil for hypertension. Installed API capacity is 30,726 MTPA.
Specialty Chemicals (₹364.96 crore) makes ethyl acetate at 120,000 MTPA, acetic anhydride at 32,000 MTPA, iso butyl benzene at 12,000 MTPA, mono chloro acetic acid at 7,200 MTPA, acetyl chloride at 5,200 MTPA, and now triacetin at 6,000 MTPA. Total installed capacity across both segments is 213,126 MTPA.
Here is where it gets structurally amusing. IBB, MCA and acetyl chloride are all listed as inputs for ibuprofen. Acetic anhydride is the major input for paracetamol. Which means the chemicals division’s biggest customer is a building on the same road, and ₹78.19 crore of inter-segment revenue this quarter is essentially IOL invoicing IOL — the most reliable receivable in the business.
CARE describes this as backward integration providing “greater control over supply chain costs.” The plant itself runs reactions, filtration, centrifugation, drying, blending, sieving and micronization, with utilities spanning −20 to 275°C, a four-stage zero-discharge effluent treatment plant, and 185 MTPH of steam. The R&D division has 120 professionals including 50-plus scientists, and
